Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Csl ADR CSLLY

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Add To Watchlist

Recent & Breaking News (OTCQX:CSLLY)

Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services

PR Newswire May 27, 2020

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

PR Newswire May 26, 2020

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

PR Newswire May 7, 2020

CSL Behring Announces Results from Three Analyses of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) in Primary Immunodeficiency (PI)

PR Newswire April 21, 2020

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

PR Newswire April 8, 2020

Seqirus Receives FDA Approval for FLUAD® QUADRIVALENT (Influenza Vaccine, Adjuvanted) for Adults 65 Years and Older

PR Newswire February 24, 2020

University City Science Center partnership with CSL Behring accelerates the search for new biotherapies at the University of Pittsburgh and the University of Delaware

PR Newswire February 13, 2020

PRIVIGEN® (Immune Globulin Intravenous (Human), 10% Liquid) Granted Orphan-Drug Designation for the Investigational Treatment of Systemic Sclerosis (SSc)

PR Newswire February 11, 2020

Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine

PR Newswire February 3, 2020

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

PR Newswire January 24, 2020

Forbes Magazine Ranks CSL Behring Among Best Employers for Diversity

PR Newswire January 21, 2020

Researchers decipher a new way that immune cells detect infections and cancers

PR Newswire January 10, 2020

Global Biotech Leader CSL to Present at 38th Annual J.P. Morgan Healthcare Conference

PR Newswire January 9, 2020

Harvard Business Review Names CSL's Paul Perreault Among Best Performing CEOs in the World

PR Newswire October 24, 2019

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats

PR Newswire September 26, 2019

Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses

PR Newswire August 31, 2019

Seqirus Presents New Clinical Data that Reinforce the Ability of MF59® Adjuvanted Seasonal and Pandemic Influenza Vaccines to Increase Immune Response

PR Newswire August 30, 2019

Seqirus to Present Data on Pandemic and Seasonal Influenza Vaccines at OPTIONS X Conference

PR Newswire August 22, 2019

Anjana Narain to Lead Seqirus Influenza Vaccines Business

PR Newswire July 17, 2019

Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines

PR Newswire July 15, 2019